Compositions and methods for the treatment of anorectal disorders

A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith, said composition comprising a phosphodiesterase inhibitor and a pharmaceutically acceptable carrier.

A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith, said composition comprising a β-adrenergic agonist and a pharmaceutically acceptable carrier.

A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith, said composition comprising an ATP-sensitive K+ channel activator and a pharmaceutically acceptable carrier.

A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith, said composition comprising an α1-adrenergic antagonist and a pharmaceutically acceptable carrier.

A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith said composition comprising a cAMP-dependent protein kinase activator and an L-type Ca2+ channel blocker.

A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith, said composition comprising a cGMP-dependent protein kinase activator and a pharmaceutically acceptable carrier.

A composition for the treatment of an anorectal disorder, and for controlling the pain associated therewith, said composition comprising a nonspecific cyclic nucleotide-dependent protein kinase activator, optionally in admixture with a smooth muscle relaxant.

A method of treating an anorectal disorder, and for controlling the pain associated therewith, the method comprising administering to a subject in need of such treatment a therapeutically effective amounts of a NO donor and a second agent selected from the group consisting of phosphodiesterase type II inhibitors, phosphodiesterase type IV inhibitors, phosphodiesterase type V inhibitors, nonspecific phosphodiesterase inhibitors, superoxide scavengers, β-adrenergic agonists, cAMP-dependent protein kinase activators, α1-adrenergic antagonists, estrogens, L-type Ca2+ channel blockers, ATP-sensitive K+ channel activators and smooth muscle relaxants.

A method of treating an anorectal disorder, and for controlling the pain associated therewith, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a phosphodiesterase inhibitor.

A method of treating an anorectal disorder, and for controlling the pain associated therewith, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a β-adrenergic agonist.

A method of treating an anorectal disorder, and for controlling the pain associated therewith, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising an ATP-sensitive potassium channel opener and an agent that promotes cAMP-mediated anal sphincter relaxation.

A method of treating an anorectal disorder, and for controlling the pain associated therewith, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a potassium channel opener, wherein said therapeutically effective amount decreases hypertonicity of an anal sphincter muscle of the subject.

A method of treating an anorectal disorder, and for controlling the pain associated therewith, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and an agent which increases a level of cyclic guanidine monophosphate or cyclic adenosine monophosphate in a tissue of an anal sphincter muscle of the subject, thereby decreasing hypertonicity of the anal sphincter muscle of the subject.